Private Management Group Inc. raised its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 34.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 999,470 shares of the company’s stock after buying an additional 256,269 shares during the quarter. Private Management Group Inc. owned about 0.10% of Teva Pharmaceutical Industries Limited worth $17,591,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in TEVA. Capital Research Global Investors boosted its holdings in shares of Teva Pharmaceutical Industries Limited by 13.8% in the 2nd quarter. Capital Research Global Investors now owns 76,325,059 shares of the company’s stock worth $2,535,518,000 after purchasing an additional 9,260,426 shares during the period. Franklin Resources Inc. boosted its holdings in shares of Teva Pharmaceutical Industries Limited by 11.1% in the 2nd quarter. Franklin Resources Inc. now owns 66,796,897 shares of the company’s stock worth $2,218,958,000 after purchasing an additional 6,685,844 shares during the period. FMR LLC boosted its holdings in shares of Teva Pharmaceutical Industries Limited by 16.7% in the 2nd quarter. FMR LLC now owns 42,844,979 shares of the company’s stock worth $1,423,310,000 after purchasing an additional 6,115,853 shares during the period. Capital World Investors boosted its holdings in shares of Teva Pharmaceutical Industries Limited by 41.9% in the 2nd quarter. Capital World Investors now owns 11,068,200 shares of the company’s stock worth $367,686,000 after purchasing an additional 3,268,200 shares during the period. Finally, Alliancebernstein L.P. boosted its holdings in shares of Teva Pharmaceutical Industries Limited by 32.3% in the 2nd quarter. Alliancebernstein L.P. now owns 11,399,400 shares of the company’s stock worth $378,688,000 after purchasing an additional 2,782,257 shares during the period. Institutional investors and hedge funds own 55.81% of the company’s stock.

TEVA has been the subject of a number of recent research reports. TheStreet cut Teva Pharmaceutical Industries Limited from a “c-” rating to a “d+” rating in a report on Friday, August 25th. ValuEngine cut Teva Pharmaceutical Industries Limited from a “buy” rating to a “hold” rating in a report on Friday, September 1st. Evercore ISI set a $38.00 price objective on Teva Pharmaceutical Industries Limited and gave the company a “buy” rating in a report on Wednesday, October 25th. Deutsche Bank AG restated a “buy” rating and set a $28.00 price objective (down previously from $43.00) on shares of Teva Pharmaceutical Industries Limited in a report on Wednesday, August 9th. Finally, Cantor Fitzgerald set a $17.00 price objective on Teva Pharmaceutical Industries Limited and gave the company a “hold” rating in a report on Thursday, October 26th. Seven equities research analysts have rated the stock with a sell rating, seventeen have issued a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $21.99.

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded up $0.73 during mid-day trading on Wednesday, reaching $12.49. The company had a trading volume of 24,410,002 shares, compared to its average volume of 15,165,021. Teva Pharmaceutical Industries Limited has a 1 year low of $10.85 and a 1 year high of $39.50. The company has a current ratio of 0.96, a quick ratio of 0.66 and a debt-to-equity ratio of 1.20. The stock has a market cap of $12,590.00, a P/E ratio of 2.71 and a beta of 0.52.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th will be paid a dividend of $0.085 per share. The ex-dividend date is Monday, November 27th. This represents a $0.34 annualized dividend and a yield of 2.72%. Teva Pharmaceutical Industries Limited’s dividend payout ratio (DPR) is -16.01%.

TRADEMARK VIOLATION NOTICE: This story was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/11/15/teva-pharmaceutical-industries-limited-teva-shares-bought-by-private-management-group-inc.html.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Stock Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related stocks with our FREE daily email newsletter.